Lentivirus-mediated estrogen receptor α overexpression in the central nervous system ameliorates experimental autoimmune encephalomyelitis in mice

Hu,Xiao; Qin,Xinyue

doi:10.3892/ijmm.2013.1306

Lentivirus-mediated estrogen receptor α overexpression in the central nervous system ameliorates experimental autoimmune encephalomyelitis in mice

Authors:
- Xiao Hu
- Xinyue Qin
View Affiliations

Affiliations: Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: March 15, 2013 https://doi.org/10.3892/ijmm.2013.1306
Pages: 1209-1221

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple sclerosis (MS) is an autoimmune disease characterized by inflammatory cell infiltration of the central nervous system (CNS) and multifocal demyelination. Clinical data and clinical indicators demonstrate that estrogen improves the relapse-remittance of MS patients. This study aimed to investigate the anti-inflammatory effects and the underlying mechanism(s) of action of estrogen and estrogen receptor α (ERα) in an experimental autoimmune encephalomyelitis (EAE) mouse model of MS. An ERα recombinant lentivirus was constructed. Mouse neurons were cultured in serum-free culture medium, and ERα recombinant lentivirus with a multiplicity of infection (MOI) of 5 was used to infect the neurons. Furthermore, neuronal ERα mRNA and protein expression were detected using real-time quantitative PCR and western blot analysis. We sterotaxically injected ERα recombinant lentivirus into the lateral ventricle of mouse brains, and successfully identified infected neurons using Flag immunofluorescence staining to determine the optimal dose. A total of 75 C57BL/6 mice were ovariectomized. After 2 weeks, EAE was induced with myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide. The EAE mice were divided into 5 groups: the estrogen group (treatment with estradiol), the ERα agonist group (treatment with raloxifene), the ERα recombinant lentivirus group (ERα group, treatment with ERα recombinant lentivirus), the empty virus group and the normal saline (NS) group; clinical symptoms and body weight were compared among the groups. We assessed EAE-related parameters, detected pathological changes with immunohistochemistry and quantified the expression of myelin basic protein (MBP), matrix metalloproteinase-9 (MMP-9), and a subset of EAE-related cytokines using enzyme-linked immunosorbent assay (ELISA). We successfully constructed an ERα recombinant lentivirus. C57BL/6 mouse neurons can survive in culture for at least 8 weeks. During that period, the recombinant lentivirus was able to infect the neurons, while sustaining green fluorescence protein (GFP) expression. ERα recombinant lentivirus also infected the neurons at a MOI of 5. The ERα mRNA and protein expression levels were higher in the infected neurons compared to the uninfected ones. We successfully infected the CNS of C57BL/6 mice by stereotaxically injecting ERα recombinant lentivirus into the lateral ventricle of the mouse brains and induced EAE. The lentivirus-mediated overexpression of ERα reduced the incidence of EAE, ameliorated the clinical symptoms, inhibited inflammatory cell CNS infiltration, and reduced nerve fiber demyelination. MMP-9, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin (IL)-17 and IL-23 expression levels were decreased, while those of MBP and IL-4 were increased. These data demonstrate that it is possible to induce the overexpression of ERα using a recombinant lentivirus, and that this novel intervention ameliorates EAE in a mouse model. Mechanistically, estrogen and ERα inhibit inflammatory responses, and ERα alleviates damage to the myelin sheath. Collectively, our findings support the potential use of ERα as a therapeutic target for the treatment of MS.

View Figures

View References

1	Ouallet J, Baumann N, Marie Y and Villarroya H: Fas system up-regulation in experimental autoimmune encephalomyelitis. J Neurol Sci. 170:96–104. 1999. View Article : Google Scholar : PubMed/NCBI
2	Barac-Latas V, Muhvic D and Radosevic-Stabic B: The influence of pregnancy on development and course of chronic relapsing experimental autoimmune encephalomyelitis in rats: implications for multiple sclerosis. Coll Antropol. 34(Suppl 1): 267–271. 2010.
3	Runmarker B and Andersen O: Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain. 118:253–261. 1995. View Article : Google Scholar : PubMed/NCBI
4	Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P and Moreau T: Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 339:285–291. 1998. View Article : Google Scholar : PubMed/NCBI
5	Niino M, Hirotani M, Fukazawa T, Kikuchi S and Sasaki H: Estrogens as potential therapeutic agents in multiple sclerosis. Cent Nerv Syst Agents Med Chem. 9:87–94. 2009. View Article : Google Scholar : PubMed/NCBI
6	Sicotte NL, Liva SM, Klutch R, et al: Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol. 52:421–428. 2002. View Article : Google Scholar : PubMed/NCBI
7	Soldan SS, Alvarez Retuerto AI, Sicotte NL and Voskuhl RR: Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol. 171:6267–6274. 2003. View Article : Google Scholar : PubMed/NCBI
8	Lelu K, Laffont S, Delpy L, et al: Estrogen receptor alpha signaling in T lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell differentiation and protection against experimental autoimmune encephalomyelitis. J Immunol. 187:2386–2393. 2011. View Article : Google Scholar
9	Wang C, Dehghani B, Li Y, et al: Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J Immunol. 182:3294–3303. 2009. View Article : Google Scholar
10	Bodhankar S, Wang C, Vandenbark AA and Offner H: Estrogen- induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. Eur J Immunol. 41:1165–1175. 2011. View Article : Google Scholar : PubMed/NCBI
11	Subramanian S, Yates M, Vandenbark AA and Offner H: Oestrogen-mediated protection of experimental autoimmune encephalomyelitis in the absence of Foxp3⁺ regulatory T cells implicates compensatory pathways including regulatory B cells. Immunology. 132:340–347. 2011.PubMed/NCBI
12	Gold SM and Voskuhl RR: Estrogen treatment in multiple sclerosis. J Neurol Sci. 286:99–103. 2009. View Article : Google Scholar : PubMed/NCBI
13	MacKenzie-Graham AJ, Rinek GA, Avedisian A, et al: Estrogen treatment prevents gray matter atrophy in experimental autoimmune encephalomyelitis. J Neurosci Res. 90:1310–1323. 2012. View Article : Google Scholar : PubMed/NCBI
14	Ziehn MO, Avedisian AA, Dervin SM, O’Dell TJ and Voskuhl RR: Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease. Lab Invest. 92:1234–1245. 2012. View Article : Google Scholar : PubMed/NCBI
15	Giraud SN, Caron CM, Pham-Dinh D, Kitabgi P and Nicot AB: Estradiol inhibits ongoing autoimmune neuroinflammation and NFkappaB-dependent CCL2 expression in reactive astrocytes. Proc Natl Acad Sci USA. 107:8416–8421. 2010. View Article : Google Scholar : PubMed/NCBI
16	Bodhankar S and Offner H: Gpr30 forms an integral part of E2-protective pathway in experimental autoimmune encephalomyelitis. Immunol Endocr Metab Agents Med Chem. 11:262–274. 2011. View Article : Google Scholar : PubMed/NCBI
17	Matejuk A, Bakke AC, Hopke C, Dwyer J, Vandenbark AA and Offner H: Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis. J Neurosci Res. 77:119–126. 2004. View Article : Google Scholar
18	Tiwari-Woodruff S and Voskuhl RR: Neuroprotective and anti-inflammatory effects of estrogen receptor ligand treatment in mice. J Neurol Sci. 286:81–85. 2009. View Article : Google Scholar : PubMed/NCBI
19	Du S, Sandoval F, Trinh P, Umeda E and Voskuhl R: Estrogen receptor-beta ligand treatment modulates dendritic cells in the target organ during autoimmune demyelinating disease. Eur J Immunol. 41:140–150. 2011. View Article : Google Scholar
20	Blasko E, Haskell CA, Leung S, et al: Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J Neuroimmunol. 214:67–77. 2009. View Article : Google Scholar : PubMed/NCBI
21	Subramanian S, Miller LM, Grafe MR, Vandenbark AA and Offner H: Contribution of GPR30 for 1,25 dihydroxyvitamin D(3) protection in EAE. Metab Brain Dis. 27:29–35. 2012. View Article : Google Scholar : PubMed/NCBI
22	Lelu K, Delpy L, Robert V, et al: Endogenous estrogens, through estrogen receptor alpha, constrain autoimmune inflammation in female mice by limiting CD4⁺ T-cell homing into the CNS. Eur J Immunol. 40:3489–3498. 2010. View Article : Google Scholar : PubMed/NCBI
23	Gold SM, Sasidhar MV, Morales LB, et al: Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). Lab Invest. 89:1076–1083. 2009. View Article : Google Scholar
24	Spence RD, Hamby ME, Umeda E, et al: Neuroprotection mediated through estrogen receptor-alpha in astrocytes. Proc Natl Acad Sci USA. 108:8867–8872. 2011. View Article : Google Scholar : PubMed/NCBI
25	Wong LF, Goodhead L, Prat C, Mitrophanous KA, Kingsman SM and Mazarakis ND: Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. Hum Gene Ther. 17:1–9. 2006. View Article : Google Scholar : PubMed/NCBI
26	Foster TC, Rani A, Kumar A, Cui L and Semple-Rowland SL: Viral vector-mediated delivery of estrogen receptor-alpha to the hippocampus improves spatial learning in estrogen receptor-alpha knockout mice. Mol Ther. 16:1587–1593. 2008. View Article : Google Scholar
27	Brewer GJ, Torricelli JR, Evege EK and Price PJ: Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurol Sci. 35:567–576. 1993.PubMed/NCBI
28	Hu X, Lei L, Yuan J, Xing W, WJY and Qin X: Construction of recombinant lentivirus carrying mouse estrogen receptor α and identification in infected neurons. Acad J Sec Mil Med Univ. 32:160–166. 2011.
29	Tiwari-Woodruff S, Morales LB, Lee R and Voskuhl RR: Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment. Proc Natl Acad Sci USA. 104:14813–14818. 2007. View Article : Google Scholar : PubMed/NCBI
30	Tapia-Gonzalez S, Carrero P, Pernia O, Garcia-Segura LM and Diz-Chaves Y: Selective Er modulators reduce microglia reactivity in vivo after peripheral inflammation: potential role of microglial ERs. J Endocrinol. 198:219–230. 2008. View Article : Google Scholar : PubMed/NCBI
31	Legge KL, Min B, Bell JJ, et al: Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis. J Exp Med. 191:2039–2052. 2000. View Article : Google Scholar
32	Murphy AC, Lalor SJ, Lynch MA and Mills KH: Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun. 24:641–651. 2010. View Article : Google Scholar : PubMed/NCBI
33	Jacobs EC: Genetic alterations in the mouse myelin basic proteins result in a range of dysmyelinating disorders. J Neurol Sci. 228:195–197. 2005. View Article : Google Scholar : PubMed/NCBI
34	Molineaux SM, Engh H, De Ferra F, Hudson L and Lazzarini RA: Recombination within the myelin basic protein gene created the dysmyelinating shiverer mouse mutation. Proc Natl Acad Sci USA. 83:7542–7546. 1986. View Article : Google Scholar : PubMed/NCBI
35	Fainardi E, Castellazzi M, Bellini T, et al: Cerebrospinal fluid and serum levels and intrathecal production of active MMP-9 as markers of disease activity in patients with multiple sclerosis. Mult Scler. 12:294–301. 2006. View Article : Google Scholar : PubMed/NCBI
36	Kurzepa J, Bartosik-Psujek H, Suchozebrska-Jesionek D, Rejdak K, Stryjecka-Zimmer M and Stelmasiak Z: Role of matrix metalloproteinases in the pathogenesis of multiple sclerosis. Neurol Neurochir Pol. 39:63–67. 2005.(In Polish).
37	Rubinson DA, Dillon CP, Kwiatkowski AV, et al: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 33:401–406. 2003. View Article : Google Scholar : PubMed/NCBI
38	Trobridge G and Russell DW: Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors. J Virol. 78:2327–2335. 2004. View Article : Google Scholar : PubMed/NCBI
39	Yip PK, Wong LF, Pattinson D, et al: Lentiviral vector expressing retinoic acid receptor beta2 promotes recovery of function after corticospinal tract injury in the adult rat spinal cord. Hum Mol Genet. 15:3107–3118. 2006. View Article : Google Scholar : PubMed/NCBI
40	Ambrosino C, Tarallo R, Bamundo A, et al: Identification of a hormone-regulated dynamic nuclear actin network associated with estrogen receptor alpha in human breast cancer cell nuclei. Mol Cell Proteomics. 9:1352–1367. 2010. View Article : Google Scholar
41	Vigna E and Naldini L: Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med. 2:308–316. 2000. View Article : Google Scholar : PubMed/NCBI
42	Bruck W: The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol. 252(Suppl 5): v3–v9. 2005. View Article : Google Scholar : PubMed/NCBI
43	Liu HY, Buenafe AC, Matejuk A, et al: Estrogen inhibition of EAE involves effects on dendritic cell function. J Neurol Sci. 70:238–248. 2002.PubMed/NCBI
44	Baumann N and Pham-Dinh D: Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev. 81:871–927. 2001.PubMed/NCBI
45	Daigle JL, Hong JH, Chiang CS and McBride WH: The role of tumor necrosis factor signaling pathways in the response of murine brain to irradiation. Cancer Res. 61:8859–8865. 2001.PubMed/NCBI
46	Griffiths I, Klugmann M, Anderson T, et al: Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science. 280:1610–1613. 1998. View Article : Google Scholar : PubMed/NCBI
47	De Rosbo NK and Bernard CC: Multiple sclerosis brain immunoglobulins stimulate myelin basic protein degradation in human myelin: a new cause of demyelination. J Neurochem. 53:513–518. 1989.PubMed/NCBI
48	Einstein ER, Csejtey J, Dalal KB, Adams CW, Bayliss OB and Hallpike JF: Proteolytic activity and basic protein loss in and around multiple sclerosis plaques: combined biochemical and histochemical observations. J Neurochem. 19:653–662. 1972. View Article : Google Scholar
49	Harauz G, Ishiyama N, Hill CM, Bates IR, Libich DS and Fares C: Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. Micron. 35:503–542. 2004. View Article : Google Scholar
50	Crawford DK, Mangiardi M, Song B, et al: Oestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination. Brain. 133:2999–3016. 2010. View Article : Google Scholar : PubMed/NCBI
51	Garay L, Gonzalez Deniselle MC, Gierman L, et al: Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Neuroimmunomodulation. 15:76–83. 2008.PubMed/NCBI
52	Sarkaki A, Amani R, Badavi M, et al: Pre-treatment effect of different doses of soy isoflavones on spatial learning and memory in an ovariectomized animal model of Alzheimer’s disease. Pak J Biol Sci. 11:1114–1119. 2008.PubMed/NCBI
53	Sheldahl LC, Marriott LK, Bryant DM, Shapiro RA and Dorsa DM: Neuroprotective effects of estrogen and selective estrogen receptor modulators begin at the plasma membrane. Minerva Endocrinol. 32:87–94. 2007.PubMed/NCBI
54	Riggs BL and Hartmann LC: Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med. 348:618–629. 2003. View Article : Google Scholar : PubMed/NCBI
55	Chitnis T and Khoury SJ: Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis. Immunol Res. 28:223–239. 2003. View Article : Google Scholar : PubMed/NCBI
56	McGeachy MJ and Anderton SM: Cytokines in the induction and resolution of experimental autoimmune encephalomyelitis. Cytokine. 32:81–84. 2005. View Article : Google Scholar : PubMed/NCBI
57	Suryani S and Sutton I: An interferon-gamma-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis. J Neuroimmunol. 183:96–103. 2007.PubMed/NCBI
58	Butti E, Bergami A, Recchia A, et al: IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis. Gene Ther. 15:504–515. 2008. View Article : Google Scholar : PubMed/NCBI
59	Bebo BF Jr, Dehghani B, Foster S, Kurniawan A, Lopez FJ and Sherman LS: Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis. Glia. 57:777–790. 2009. View Article : Google Scholar
60	Juedes AE, Hjelmstrom P, Bergman CM, Neild AL and Ruddle NH: Kinetics and cellular origin of cytokines in the central nervous system: insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. J Immunol. 164:419–426. 2000. View Article : Google Scholar
61	Monteiro de Castro G, Eduarda Zanin M, Ventura-Oliveira D, Aparecida Vilella C, Ashimine R and De Lima Zollner R: Th1 and Th2 cytokine immunomodulation by gangliosides in experimental autoimmune encephalomyelitis. Cytokine. 26:155–163. 2004.PubMed/NCBI
62	Abraham M, Shapiro S, Karni A, Weiner HL and Miller A: Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells J Neuroimmunol. 163:157–164. 2005. View Article : Google Scholar : PubMed/NCBI
63	Correale J and Bassani Molinas Mde L: Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J Neuroimmunol. 140:198–209. 2003. View Article : Google Scholar : PubMed/NCBI
64	Illes Z, Safrany E, Peterfalvi A, et al: 3′UTR C2370A allele of the IL-23 receptor gene is associated with relapsing-remitting multiple sclerosis. Neurosci Lett. 431:36–38. 2008.
65	Harrington LE, Hatton RD, Mangan PR, et al: Interleukin 17- producing CD4⁺ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 6:1123–1132. 2005.PubMed/NCBI
66	Kawanokuchi J, Shimizu K, Nitta A, et al: Production and functions of IL-17 in microglia. J Neuroimmunol. 194:54–61. 2008. View Article : Google Scholar : PubMed/NCBI
67	Kolls JK and Linden A: Interleukin-17 family members and inflammation. Immunity. 21:467–476. 2004. View Article : Google Scholar : PubMed/NCBI
68	Tian AY, Zhang RW, Shi XG and Yu HM: Alteration of T helper cell subsets in the optic nerve of experimental autoimmune encephalomyelitis. Int J Mol Med. 25:869–874. 2010.PubMed/NCBI
69	Uyttenhove C, Sommereyns C, Theate I, Michiels T and van Snick J: Anti-IL-17A autovaccination prevents clinical and histological manifestations of experimental autoimmune encephalomyelitis. Ann NY Acad Sci. 1110:330–336. 2007. View Article : Google Scholar